Patents by Inventor Amy S. Determan
Amy S. Determan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11827754Abstract: Provided is a method of forming a fibrin hydrogel composition, the method including providing a fibrin hydrogel or precursor thereof, comprising fibrin hydrogel forming salt. The fibrin hydrogel forming salt concentration is greater than or equal to the threshold concentration to form a fibrin hydrogel. The method further includes combining the fibrin hydrogel with a carrier material. The concentration of the carrier material typically ranges from 0.1 to about 50 wt.-%. The method further includes reducing the salt concentration below the threshold concentration to form a fibrin hydrogel.Type: GrantFiled: October 4, 2017Date of Patent: November 28, 2023Assignee: 3M INNOVATIVE PROPERTIES COMPANYInventors: Jason W. Bjork, Amy S. Determan, Jonathan J. O'Hare, Robert A. Asmus, James P. Dizio, Zhicheng Tian
-
Publication number: 20230067731Abstract: An example debriding pad includes a support layer, a first region, and a second region. The first region includes a first material defining a plurality of first loop piles arranged on the support material. The second region includes a second material defining a plurality of second loop piles arranged on the support material. The second material is stiffer than the first material to provide more aggressive debridement of a wound.Type: ApplicationFiled: April 26, 2021Publication date: March 2, 2023Inventors: Amy K. McNulty, Amy S. Determan, Sarah L. Isakson
-
Publication number: 20210324150Abstract: The invention includes a forced-air blanket for providing a profusion of air to a patient, comprising a bottom layer with a plurality of openings configured to allow a profusion of air to pass through the bottom layer and an upper layer bonded to the bottom layer around a periphery, wherein the upper layer is also bonded to bottom layer by a plurality of linear seals and a plurality of staked seals. In an embodiment, at least one of more of the linear seals have one end which is joined to a portion of the periphery. In another embodiment, the forced-air blanket may further include at least one elongated seal that is positioned proximate to the inlet. The arrangement of the plurality of staked seals, elongated seals and linear seals assists in providing a blanket that is of a low-profile with even air distribution.Type: ApplicationFiled: October 4, 2017Publication date: October 21, 2021Applicant: 3M INNOVATIVE PROPERTIES COMPANYInventors: Jason W. Bjork, AMY S. DETERMAN, JONATHAN J. O'HARE, ROBERT A. ASMUS, JAMES P. DIZIO, ZHICHENG TIAN
-
Publication number: 20210100929Abstract: Disclosed is a fibrinogen composition. The fibrinogen composition comprises denatured fibrinogen hydrogel having a fibrinogen concentration ranging from 0.1 to 15 wt.-% and a fibrinogen hydrogel forming salt at a concentration less than a threshold concentration to form the fibrinogen hydrogel. In some examples, the fibrinogen composition is dehydrated denatured fibrinogen hydrogel, where the fibrinogen composition comprises salt at a concentration no greater than 20 wt.-%.Type: ApplicationFiled: November 23, 2020Publication date: April 8, 2021Applicant: 3M INNOVATIVE PROPERTIES COMPANYInventors: JAMES P. DIZIO, ZHICHENG TIAN, JAMES W. BJORK, AMY S. DETERMAN, ROBERT A. ASMUS, JONATHAN J. O'HARE
-
Patent number: 10940233Abstract: Provided is a method of forming a fibrinogen hydrogel composition, the method including providing a fibrinogen hydrogel or precursor thereof, comprising fibrinogen hydrogel forming salt. The fibrinogen hydrogel forming salt concentration is greater than or equal to the threshold concentration to form a fibrinogen hydrogel. The method further includes denaturing the fibrinogen hydrogel such as by heating. The method optionally further includes combining the fibrinogen hydrogel with a carrier material. When present, the concentration of the carrier material typically ranges from 0.1 to about 50 wt.-%. The method further includes reducing the salt concentration below the threshold concentration to form a fibrinogen hydrogel.Type: GrantFiled: October 4, 2017Date of Patent: March 9, 2021Assignee: 3M Innovative Properties CompanyInventors: James P. Dizio, Zhicheng Tian, Jason W. Bjork, Amy S. Determan, Robert A. Asmus, Jonathan J. O'Hare
-
Publication number: 20210052705Abstract: The present invention provides compositions, devices, methods and processes related to the intradermal delivery of PTHrP and PTHrP analogues, particularly [Glu22,25, Leu23,28,31, Aib29, Lys26,30]hPTHrP(1-34)NH2.Type: ApplicationFiled: August 31, 2020Publication date: February 25, 2021Applicants: Radius Health, Inc., Kindeva Drug Delivery L.P.Inventors: Gary Hattersley, Kris J. Hansen, Amy S. Determan, Ying Zhang
-
Publication number: 20200038546Abstract: Provided is a method of forming a fibrinogen hydrogel composition, the method including providing a fibrinogen hydrogel or precursor thereof, comprising fibrinogen hydrogel forming salt. The fibrinogen hydrogel forming salt concentration is greater than or equal to the threshold concentration to form a fibrinogen hydrogel. The method further includes denaturing the fibrinogen hydrogel such as by heating. The method optionally further includes combining the fibrinogen hydrogel with a carrier material. When present, the concentration of the carrier material typically ranges from 0.1 to about 50 wt.-%. The method further includes reducing the salt concentration below the threshold concentration to form a fibrinogen hydrogel.Type: ApplicationFiled: October 4, 2017Publication date: February 6, 2020Applicant: 3M INNOVATIVE PROPERTIES COMPANYInventors: JAMES P. DIZIO, ZHICHENG TIAN, JASON W. BJORK, AMY S. DETERMAN, ROBERT A. ASMUS, JONATHAN J. O'HARE
-
Publication number: 20200030486Abstract: A method of forming a fibrin hydrogel composition including providing one or more unitary masses of a fibrin hydrogel, dividing at least one of the unitary masses of the fibrin hydrogel into a multiplicity of smaller pieces of the fibrin hydrogel, and recombining at least a portion of the smaller pieces into a cohesive mass. Dividing at least one of the unitary masses of fibrin hydrogel into a multiplicity of smaller pieces may include shearing or cutting the unitary masses to form an aqueous dispersion of the fibrin hydrogel in an aqueous medium. The aqueous dispersion of fibrin hydrogel may be applied to a substrate on a roller or an endless belt, and is optionally overlaid by a scrim. The cohesive mass of fibrin hydrogel, which may be formed by removing at least a portion of the aqueous medium from the aqueous dispersion of the smaller pieces of the fibrin hydrogel, finds uses in wound dressing articles.Type: ApplicationFiled: October 3, 2017Publication date: January 30, 2020Inventors: Jonathan J. O'HARE, Mikhail L. PEKUROVSKY, Amy S. DETERMAN, Gino L. PITERA, Jason W. BJORK, Daniel V. NORTON, Robert A. ASMUS
-
Publication number: 20190290738Abstract: The present invention provides compositions, devices, methods and processes related to the intradermal delivery of PTHrP and PTHrP analogues, particularly [Glu22,25, Leu23,28,31, Aib29, Lys26,30]hPTHrP(1-34)NH2.Type: ApplicationFiled: February 19, 2019Publication date: September 26, 2019Applicants: Radius Health, Inc., 3M Innovative Properties Company, a wholly owned subsidiary of 3M CompanyInventors: Gary Hattersley, Kris J. Hansen, Amy S. Determan, Ying Zhang
-
Publication number: 20180344631Abstract: A medical device, comprising: an array of microneedles, and a coating disposed on the microneedles, wherein the coating comprises: a local anesthetic selected from the group consisting of lidocaine, prilocaine, and a combination thereof; and a local anesthetic dose-extending component selected from the group consisting of tetracaine, ropivacaine, bupivacaine, procaine and a combination thereof; wherein the local anesthetic is present in an amount of at least 1 wt-% based upon total weight of solids in the coating, and wherein the local anesthetic and dose-extending component are in a non-eutectic weight ratio; a medical device, comprising an array of dissolvable microneedles, the microneedles comprising: a dissolvable matrix material; at least 1 wt-% of a local anesthetic selected from the group consisting of lidocaine, prilocaine, and a combination thereof; and a local anesthetic dose-extending component selected from the group consisting of tetracaine, ropivacaine, bupivacaine, procaine and a combination thType: ApplicationFiled: August 9, 2018Publication date: December 6, 2018Inventors: Ying Zhang, Kristen J. Hansen, Amy S. Determan
-
Patent number: 10098980Abstract: Multilayer articles having an absorbent nonwoven layer and a barrier layer are described, including those having a surfactant-treated, aliphatic polyester, nonwoven absorbent layer and a barrier layer. Multilayer articles including a tie layer used to enhance the bond between the hydrophilic absorbent layer and the barrier layer are also described. Methods of making and using such articles are also described.Type: GrantFiled: October 11, 2013Date of Patent: October 16, 2018Assignee: 3M INNOVATIVE PROPERTIES COMPANYInventors: Korey W. Karls, Matthew T. Scholz, Jeffrey O. Emslander, Amy S Determan
-
Publication number: 20170189493Abstract: The present invention provides compositions, devices, methods and processes related to the intradermal delivery of PTHrP and PTHrP analogues, particularly [Glu22,25, Leu23,28,31, Aib29, Lys26,30]hPTHrP(1-34)NH2.Type: ApplicationFiled: November 14, 2016Publication date: July 6, 2017Inventors: Gary HATTERSLEY, Kris J. HANSEN, Amy S. DETERMAN, Ying ZHANG
-
Patent number: 9693950Abstract: Aqueous formulations that include at least one active pharmaceutical ingredient; and at least one excipient, wherein the aqueous formulation has a viscosity of from 500 to 30,000 centipoise when measured at a shear rate of 100 s?1 and a temperature of 25° C.; a surface tension that is not greater than 60 dynes/cm when measured under ambient conditions; or a contact angle on a medical grade polymeric material of 50° or greater when measured under ambient conditions. Methods of coating and coated microneedle arrays using the aqueous formulations are also disclosed herein.Type: GrantFiled: May 26, 2011Date of Patent: July 4, 2017Assignee: 3M INNOVATIVE PROPERTIES COMPANYInventors: Amy S. Determan, Peter R. Johnson, Joan T. Moseman, Ryan T. Woldt, Kristen J. Hansen
-
Publication number: 20150283285Abstract: Multilayer articles having an absorbent nonwoven layer and a barrier layer are described, including those having a surfactant-treated, aliphatic polyester, nonwoven absorbent layer and a barrier layer. Multilayer articles including a tie layer used to enhance the bond between the hydrophilic absorbent layer and the barrier layer are also described. Methods of making and using such articles are also described.Type: ApplicationFiled: October 11, 2013Publication date: October 8, 2015Inventors: Korey W. Karls, Matthew T. Scholz, Jeffrey O. Emslander, Amy S. Determan
-
Publication number: 20140066842Abstract: A medical device, comprising: an array of microneedles, and a coating disposed on the microneedles, wherein the coating comprises: a local anesthetic selected from the group consisting of lidocaine, prilocalne, and a combination thereof; and a local anesthetic dose-extending component selected from the group consisting of alpha 1 adrenergic agonists, alpha 2 adrenergic agonists, and a combination thereof; wherein the local anesthetic is present in an amount of at least 1 wt-% based upon total weight of solids in the coating, and wherein the dose-extending component/local anesthetic weight ratio is at least 0.Type: ApplicationFiled: March 6, 2012Publication date: March 6, 2014Applicant: 3M INNOVATIVE PROPERTIES COMPANYInventors: Ying Zhang, Kristen J. Hansen, Amy S. Determan
-
Publication number: 20140066843Abstract: A medical device, comprising: an array of microneedles, and a coating disposed on the microneedles, wherein the coating comprises: a local anesthetic selected from the group consisting of lidocaine, prilocaine, and a combination thereof; and a local anesthetic dose-extending component selected from the group consisting of tetracaine, ropivacaine, bupivacaine, procaine and a combination thereof; wherein the local anesthetic is present in an amount of at least 1 wt-% based upon total weight of solids in the coating, and wherein the local anesthetic and dose-extending component are in a non-eutectic weight ratio; a medical device, comprising an array of dissolvable microneedles, the microneedles comprising: a dissolvable matrix material; at least 1 wt-% of a local anesthetic selected from the group consisting of lidocaine, prilocaine, and a combination thereof; and a local anesthetic dose-extending component selected from the group consisting of tetracaine, ropivacaine, bupivacaine, procaine and a combination thType: ApplicationFiled: March 6, 2012Publication date: March 6, 2014Applicant: 3M INNOVATIVE PROPERTIES COMPANYInventors: Ying Zhang, Kristen J. Hansen, Amy S. Determan
-
Publication number: 20130123707Abstract: Aqueous formulations that include at least one active pharmaceutical ingredient; and at least one excipient, wherein the aqueous formulation has a viscosity of from 500 to 30,000 centipoise when measured at a shear rate of 100 s?1 and a temperature of 25° C.; a surface tension that is not greater than 60 dynes/cm when measured under ambient conditions; or a contact angle on a medical grade polymeric material of 50° or greater when measured under ambient conditions. Methods of coating and coated microneedle arrays using the aqueous formulations are also disclosed herein.Type: ApplicationFiled: May 26, 2011Publication date: May 16, 2013Applicant: 3M INNOVATIVE PROPERTIES COMPANYInventors: Amy S. Determan, Peter R. Johnson, Joan T. Moseman, Ryan T. Woldt, Kristen J. Hansen
-
Publication number: 20130006217Abstract: The present invention provides compositions, devices, methods and processes related to the intradermal delivery of PTHrP and PTHrP analogues, particularly [Glu22,25, Leu23,28,31, Aib29, Lys26,30]hPTHrP(1-34)NH2.Type: ApplicationFiled: April 20, 2012Publication date: January 3, 2013Inventors: Gary Hattersley, Kris J. Hansen, Amy S. Determan, Ying Zhang